Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Giovanna ter Huizen"'
Autor:
Dennis S. Metselaar, Aimée du Chatinier, Michaël H. Meel, Giovanna ter Huizen, Piotr Waranecki, Joshua R. Goulding, Marianna Bugiani, Jan Koster, Gertjan J.L. Kaspers, Esther Hulleman
Publikováno v:
iScience, Vol 25, Iss 6, Pp 104398- (2022)
Summary: Diffuse midline gliomas (DMG) are highly malignant incurable pediatric brain tumors. In this study, we show that Aurora kinase A (AURKA) is overexpressed in DMG and can be used as a therapeutic target. Additionally, AURKA inhibition combined
Externí odkaz:
https://doaj.org/article/db96f8f4ad9a452e998e3fd3254e1990
Autor:
Margot S.F. Roeten, Johan van Meerloo, Zinia J. Kwidama, Giovanna ter Huizen, Wouter H. Segerink, Sonja Zweegman, Gertjan J.L. Kaspers, Gerrit Jansen, Jacqueline Cloos
Publikováno v:
Cells, Vol 10, Iss 3, p 665 (2021)
At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor,
Externí odkaz:
https://doaj.org/article/d4a7babdfc8741c2a36eeee2b88bbbb5
Autor:
Gertjan J.L. Kaspers, Sonja Zweegman, Johan van Meerloo, Zinia J. Kwidama, Giovanna ter Huizen, Gerrit Jansen, Jacqueline Cloos, Margot S. F. Roeten, Wouter H. Segerink
Publikováno v:
Roeten, M S F, van Meerloo, J, Kwidama, Z J, ter Huizen, G, Segerink, W H, Zweegman, S, Kaspers, G J L, Jansen, G & Cloos, J 2021, ' Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells ', Cells, vol. 10, no. 3, 665, pp. 1-15 . https://doi.org/10.3390/cells10030665
Cells
Volume 10
Issue 3
Cells, 10(3):665, 1-15. MDPI Multidisciplinary Digital Publishing Institute
Cells, Vol 10, Iss 665, p 665 (2021)
Cells
Volume 10
Issue 3
Cells, 10(3):665, 1-15. MDPI Multidisciplinary Digital Publishing Institute
Cells, Vol 10, Iss 665, p 665 (2021)
At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b163b89de767ad688c208c8b46df8a
https://research.vumc.nl/en/publications/9792b04a-da28-4ed2-81d5-a33315fdef31
https://research.vumc.nl/en/publications/9792b04a-da28-4ed2-81d5-a33315fdef31
Autor:
Gertjan J.L. Kaspers, Dennis S. Metselaar, Piotr Waranecki, Michaël H. Meel, Joshua Goulding, Angel M. Carcaboso, Giovanna ter Huizen, Esther Hulleman
Publikováno v:
Neuro-Oncology
Pediatric high-grade gliomas (pHGG) are malignant brain tumors with a high mortality rate. Radiotherapy (RT) is one of the cornerstones of current pHGG treatment, while the efficacy of chemotherapeutics remains inferior. The use of chemotherapeutics